Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Shelcal** is a marketed oral calcium and vitamin D3 supplement product line in India. The core **Shelcal 500** film-coated tablet contains calcium carbonate from powdered oyster shell, providing 500 mg elemental calcium, plus cholecalciferol 250 IU. Calcium replenishes calcium needed for skeletal mineralization and normal neuromuscular function, while cholecalciferol is converted to active vitamin D metabolites that increase intestinal calcium absorption. It is indicated for prevention and treatment of calcium and vitamin D3 deficiency and is used to support bone health. The Shelcal brand was acquired by Torrent Pharmaceuticals from Elder Pharmaceuticals in 2013. ([torrentpharma.com](https://torrentpharma.com/assets/2624_082b9f3ae0.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol (Elder Pharmaceuticals).